300 related articles for article (PubMed ID: 25996605)
1. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
2. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
3. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Ye F; Hu Y; Yu W; Xie Z; Hu J; Cao Z; Li W; Wu Y
Toxins (Basel); 2016 Apr; 8(4):115. PubMed ID: 27104568
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
[TBL] [Abstract][Full Text] [Related]
5. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
6. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
7. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
8. The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation.
Zeng Q; Lu W; Deng Z; Zhang B; Wu J; Chai J; Chen X; Xu X
J Biol Chem; 2022 Jan; 298(1):101497. PubMed ID: 34919963
[TBL] [Abstract][Full Text] [Related]
9. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
10. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
11. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
Wang J; Xiang M
Pharmacotherapy; 2013 May; 33(5):515-28. PubMed ID: 23649812
[TBL] [Abstract][Full Text] [Related]
12. Engineering a potent and specific blocker of voltage-gated potassium channel Kv1.3, a target for autoimmune diseases.
Chen R; Chung SH
Biochemistry; 2012 Mar; 51(9):1976-82. PubMed ID: 22352687
[TBL] [Abstract][Full Text] [Related]
13. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
14. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
15. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
16. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes.
Ren YR; Pan F; Parvez S; Fleig A; Chong CR; Xu J; Dang Y; Zhang J; Jiang H; Penner R; Liu JO
PLoS One; 2008; 3(12):e4009. PubMed ID: 19104661
[TBL] [Abstract][Full Text] [Related]
17. Solid phase synthesis, NMR structure determination of α-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.
Kohl B; Rothenberg I; Ali SA; Alam M; Seebohm G; Kalbacher H; Voelter W; Stoll R
Toxicon; 2015 Jul; 101():70-8. PubMed ID: 25953725
[TBL] [Abstract][Full Text] [Related]
18. Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities.
Lian YT; Yang XF; Wang ZH; Yang Y; Yang Y; Shu YW; Cheng LX; Liu K
Phytother Res; 2013 Sep; 27(9):1321-7. PubMed ID: 23132777
[TBL] [Abstract][Full Text] [Related]
19. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
20. Potassium channels, memory T cells, and multiple sclerosis.
Beeton C; Chandy KG
Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
